,267,268 Tremtelectogene empogeditemcel (trem-cel, VOR33), a CD33null HSPC product, is currently being trialed in AML in combination with post-transplant gemtuzumab ozogamicin (CD33-ADC) administration, and the results are eagerly anticipated (NCT04849910). Here, CD33 is linked to acute myeloid leukemia.